GlobeNewswire

Abeona Therapeutics Appoints Carsten Thiel, Ph.D., as Chief Executive Officer

Del
  • Company strengthens management team with biopharmaceutical veteran bringing extensive commercial experience in life-threatening rare diseases
  • Tim Miller, Ph.D. continues as president and assumes chief scientific officer role

NEW YORK and CLEVELAND, April 02, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases, today announced the appointment of Carsten Thiel, Ph.D., as Chief Executive Officer.  Timothy J. Miller, Ph.D., will remain President and assume the position of Chief Scientific Officer in charge of the company's expanding clinical and preclinical research programs. Dr. Thiel most recently served as the Executive Vice President and Chief Commercial Officer of Alexion Pharmaceuticals, Inc. where he led global commercial operations bringing innovative and life-transformative therapies for rare diseases to patients.

"The past year has been an extraordinary time in the history of Abeona, including significant progress in our clinical development programs and establishment of our new manufacturing facility in Cleveland," said Steven Rouhandeh, Executive Chairman of Abeona.  "As CEO, Carsten Thiel brings a unique combination of extensive experience in research and global rare disease commercialization to Abeona. In his recent positions, he successfully created value by building cohesive talented teams, driving the commercial success of multiple products globally and fostering entrepreneurial culture; all key aspects that will be critical to our success in these areas in the years ahead. We are very grateful to Tim Miller for his vision and leadership that have brought us to this pivotal stage in our business growth."

Dr. Thiel brings 25 years of proven global biopharmaceutical industry experience, including rare and orphan diseases, to Abeona.  Prior to leading his most recent position at Alexion, he served as its Senior Vice President, Europe/Middle East/Africa and Asia Pacific where he was responsible for driving Alexion's global commercial operations in these regions, including maximizing the current rare disease portfolio as well as guiding the launch of anticipated new products and indications. 

"I am thrilled to be joining Abeona during a period of major growth and momentum in the company's range of promising development programs," said Dr. Thiel.  "I look forward to bringing my experience in business development, biomedical research and commercialization to the outstanding Abeona team at a time when the company is ideally positioned to rapidly expand these areas."

Prior to joining Alexion, Dr. Thiel served as Vice President, Head of Europe at Amgen. In this role, he led regional operations and was responsible for multiple products in hematology/oncology, nephrology, and bone disorders, and prepared for new product launches in inflammation and cardiology. He also held various other senior leadership positions at Amgen, including General Manager, Germany, and General Manager, CEE, where he led all markets in Eastern Europe and established Amgen's operations in Russia. He also served as Head of the Oncology franchise in Europe during the time of several blockbuster product launches. Prior to Amgen, Dr. Thiel held several sales and marketing leadership roles across Europe at Roche.

"As Abeona expands our innovative science and clinical research programs into new areas, I look forward to working more closely with our research and product development teams to fuel even greater success for developing novel gene and cell therapies," said Dr. Miller. "We welcome Carsten to our team at Abeona, and remain confident that our clinical advancements and strategic decisions have solidly positioned us to plan for many promising opportunities in global product commercialization and business strategy." 

Dr. Thiel earned his doctorate in molecular biology & biochemistry at Max Planck Institute for Biophysical Chemistry in Goettingen, Germany. 

About Abeona: Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing cell and gene therapies for life-threatening rare genetic diseases. Abeona's lead programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV-NAGLU), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type B (MPS IIIB).  Abeona is also developing ABO-201 (AAV-CLN3) gene therapy for CLN3 disease (juvenile Batten disease), ABO-202 (AAV-CLN1) for treatment of CLN1 disease (infantile to late infantile Batten), EB-201 for epidermolysis bullosa (EB), ABO-301 (AAV-FANCC) for Fanconi anemia (FA) disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. In addition, Abeona is developing a proprietary vector platform, AIM(TM), for next generation product candidates.  For more information, visit www.abeonatherapeutics.com.

Investor Contact:
Christine Silverstein
SVP, Finance & Investor Relations
Abeona Therapeutics Inc.
+1 (646) 813-4707
csilverstein@abeonatherapeutics.com 

Media Contact:
Lynn Granito
Berry & Company Public Relations
+1 (212) 253-8881
lgranito@berrypr.com 

This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include statements regarding the expected expansion in our business development, biomedical research and commercialization; our belief that Dr. Miller working more closely with our research and product development teams will fuel even greater success for the development of novel gene and cell therapies; and our expectation that we have many promising opportunities in global product commercialization and business strategies.  We have attempted to identify forward looking statements by such terminology as "may," will," "anticipate," "believe," "estimate," "expect," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances), which constitute and are intended to identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, risks and uncertainties, including but not limited to, continued interest in our rare disease portfolio, our ability to enroll patients in clinical trials, the impact of competition; the ability to develop our products and technologies; the ability to secure licenses for any technology that may be necessary to commercialize our products; the ability to achieve or obtain necessary regulatory approvals; the impact of changes in the financial markets and global economic conditions; and other risks as may be detailed from time to time in the Company's Annual Reports on Form 10-K and other reports filed by the Company with the Securities and Exchange Commission. The Company undertakes no obligations to make any revisions to the forward-looking statements contained in this release or to update them to reflect events or circumstances occurring after the date of this release, whether as a result of new information, future developments or otherwise.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Abeona Therapeutics Inc via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Sanan IC Announces Commercial Release of 6-Inch SiC Wafer Foundry Process19.12.2018 15:00Pressemelding

SUNNYVALE, Calif., Dec. 19, 2018 (GLOBE NEWSWIRE) -- SANAN INTEGRATED CIRCUIT CO., LTD. (Sanan IC), a pure-play wafer foundry with its advanced compound semiconductor technology platform, today announced that it has achieved full process qualification for commercial release of its 6-inch silicon carbide (SiC) technology to add to its foundry services portfolio. Committed to providing advanced materials manufacturing capability for serving the global market, the company now offers SiC technology which has emerged as the most mature wide bandgap (WBG) semiconductor intended for circuit designs in power electronics. With the ability to ensure its supply chain, the company provides a dedicated capacity for its 6-inch SiC wafer processing services on top of its III-V compound manufacturing, namely for gallium arsenide (GaAs), gallium nitride (GaN), and indium phosphide (InP). “We are delighted to expand our wafer foundry services to now include SiC and make it commercially available to the

Finland’s National Institute for Health and Welfare joins SNOMED International as the organization’s 36th Member.19.12.2018 15:00Pressemelding

London, United Kingdom, Dec. 19, 2018 (GLOBE NEWSWIRE) -- SNOMED International and the Finnish National Institute for Health and Welfare (THL) are pleased to announce that Finland has joined the organization as its thirty-sixth Member. Finland, one of the leading nations in the area of information and communication technology, has set the development of eHealth technologies as a high priority and has quickly become a pioneer in digital health. Its largest national digital healthcare project, the Kanta Service, i.e. the National Archive of Health Information, is one of the most comprehensive systems of its kind globally, covering already the entire Finnish public healthcare sector as well as most of the private sector. The development of Kanta Service began around 2005, and the first laws concerning the digital service were enacted in 2007. A prerequisite to this being the development of information systems and standards and particularly their usability. The Kanta Service is a collabora

Plug Power to Provide Business Update on January 9, 201919.12.2018 13:00Pressemelding

Company will review 2018 success and provide 2019 projections LATHAM, N.Y., Dec. 19, 2018 (GLOBE NEWSWIRE) -- Plug Power Inc. (NASDAQ: PLUG), a leading provider of energy solutions that change the way the world moves, will hold its annual business update conference call on January 9, 2019. On this call, the Company will review successes during 2018 with customers in its GenKey, GenDrive, GenSure and ProGen product lines. Additionally, Plug Power management will provide projections expected for 2019. Save the Date: Date: January 9, 2019 Time: 10:00 am ET “2018 has been an important year, not just for Plug Power, but for the industry it leads with recording-holding metrics, including 23,000 fuel cell units deployed in the material handling market, 200 million hours of product runtime, and 16 million hydrogen fills enabled,” said Andy Marsh, CEO of Plug Power. “Plug Power has accomplished what no other hydrogen fuel cell company in the world has been able to. Of utmost importance, the Plu

Open Compute Project Announces Future Technologies Symposium19.12.2018 09:00Pressemelding

Event focused on future technology innovation to be held at the annual 2019 OCP Global Summit. San Jose, CA, Dec. 19, 2018 (GLOBE NEWSWIRE) -- For immediate release. The Open Compute Project Foundation (OCP) invites students and researchers from around the world to submit posters for the 2019 OCP Future Technologies Symposium, as a new addition to the OCP Global Summit in San Jose, CA, USA. Innovations that illustrate efficiency, scalability and scale using open source principles for scalable computing in compute, storage, networking or any OCP project; as well as those which are multi-disciplinary and cover leading technology solutions, such as edge computing. Draft papers will be reviewed by the OCP leadership, the Incubation Committee Co-Chairs and Project Leaders. Acceptance will be based on content and overall program balance. The authors of the accepted drafts will have the opportunity to submit a poster and present their work during the OCP Global Summit in San Jose, CA on March

Open Compute Project Announces Future Technologies Symposium19.12.2018 09:00Pressemelding

Event focused on future technology innovation to be held at the annual 2019 OCP Global Summit. San Jose, CA, Dec. 19, 2018 (GLOBE NEWSWIRE) -- For immediate release. The Open Compute Project Foundation (OCP) invites students and researchers from around the world to submit posters for the 2019 OCP Future Technologies Symposium, as a new addition to the OCP Global Summit in San Jose, CA, USA. Innovations that illustrate efficiency, scalability and scale using open source principles for scalable computing in compute, storage, networking or any OCP project; as well as those which are multi-disciplinary and cover leading technology solutions, such as edge computing. Draft papers will be reviewed by the OCP leadership, the Incubation Committee Co-Chairs and Project Leaders. Acceptance will be based on content and overall program balance. The authors of the accepted drafts will have the opportunity to submit a poster and present their work during the OCP Global Summit in San Jose, CA on March

LeddarTech and Cailabs Sign Collaboration Agreement on Combining LiDAR and Laser Beam Shaping Solutions for the Automotive Market19.12.2018 06:05Pressemelding

RENNES, France and QUEBEC CITY, Dec. 19, 2018 (GLOBE NEWSWIRE) -- LeddarTech, an industry leader providing the most versatile and scalable automotive LiDAR development platform, announces that it has entered an agreement with Cailabs, a French deep tech company and global leader in light shaping technology, to explore combining LeddarTech’s solid-state LiDAR technology with Cailabs’ laser beam shaping solutions for the automotive industry. A memorandum of understanding between the two parties was signed on December 13, 2018. LeddarTech delivers a proprietary auto and mobility LiDAR platform based on the LeddarEngine™ (SoC + software) enabling high-performance, low-cost LiDAR sensor solutions and that is used by large Tier-1 suppliers to develop specific LiDARs for ADAS and autonomous driving applications. Cailabs develops and produces a unique range of optical components based on its know-how and its patented technological innovations, in particular, Multi-Plane Light Conversion (MPLC)